TUESDAY, Dec. 17, 2024 (HealthDay News) -- Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with initiation of a dipeptidyl peptidase ...

Diabetic retinopathy (DR) remains the leading cause of vision loss and blindness in people of working age, in spite of the fact that current treatments are effective. Vision loss occurs in DR due ...

The risk for DR progression was lower among individuals who initiated empagliflozin vs those who began DPP4i therapy. (HealthDay News) — Empagliflozin initiation is not associated with incident ...

Treating diabetic retinopathy (DR) is still a significant challenge for clinicians and remains a leading cause of blindness worldwide. NovaGo Therapeutics is developing a human antibody therapy ...

The risk for nonproliferative diabetic retinopathy progression was similar for empagliflozin vs DPP4i therapy. (HealthDay News) — Empagliflozin initiation is not associated with incident ...

Geriatrics and Aging. 2008;11(6):333-341. Proliferative diabetic retinopathy is clinically characterized by the growth of new blood vessels that arise from the optic disc and/or retina and ...

People with type 2 diabetes who are taking empagliflozin are less likely to develop diabetic retinopathy compared to those not using the drug, new evidence has revealed. A recent study from the ...

Ip, MD, discusses the available treatments for nonproliferative diabetic retinopathy. Ip said about 50% of responders to an American Society of Retina Specialists survey reported that they were ...

Notably, he had been followed for mild to moderate nonproliferative diabetic retinopathy in both eyes without other significant findings for several years and had not seen an ophthalmologist for ...

Diabetic retinopathy involves the changes for the blood vessels in your eye due to the high sugars that are in your body from diabetes, if you're a diabetic and you notice changes to your vision ...